©The Author(s) 2025.
World J Crit Care Med. Dec 9, 2025; 14(4): 111054
Published online Dec 9, 2025. doi: 10.5492/wjccm.v14.i4.111054
Published online Dec 9, 2025. doi: 10.5492/wjccm.v14.i4.111054
Table 2 Comparison of ivabradine and beta-blockers
| Variable | Ivabradine | Beta-blockers |
| Mechanism | Blocks If channels in SA node (reduces HR only) | Block β1/β2-adrenergic receptors (reduces HR + BP) |
| Common side effects | Luminous phenomena (visual brightness). Bradycardia. Headache. Rare: Atrial fibrillation | Fatigue. Cold. hands/feet. Bronchospasm (worsens COPD/asthma) Erectile dysfunction. Sleep disturbances. Depression |
| Metabolic effects | Neutral (no impact on glucose/Lipids) | May worsen: Insulin resistance. Triglycerides (↑). HDL (↓) |
| Contraindications | HR < 60 bpm. Acute heart failure. Pacemaker-dependent | Asthma/COPD. Severe bradycardia. Heart block (2nd/3rd degree) |
| Advantages | Pure HR control. Safe in lung diseases. No sexual dysfunction. No metabolic interference | Broader benefits (angina, HTN, post-MI). Lower cost |
| Uses | COPD/asthma patients. Diabetes patients. HR reduction without BP effects | Hypertension. Post-heart attack. Arrhythmias |
- Citation: Mukesh A, Sharma A, Kothari N. Ivabradine in acute care: Revisiting the funny current in critical care context. World J Crit Care Med 2025; 14(4): 111054
- URL: https://www.wjgnet.com/2220-3141/full/v14/i4/111054.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v14.i4.111054